Phase 4
N=17
Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy
Renal Calculus · Kidney Stones
Bottom Line
View on ClinicalTrials.gov: NCT00765128 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Jan 2012
Primary outcome: Primary: Pain 'Right Now' — 1.0; 0.9 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Ketorolac (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Nov 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain 'Right Now' |
1.0; 0.9 | — |
| PRIMARY Morphine Equivalents of Concomitant Pain Medication |
15; 10 | — |
Summary
The purpose of this study is to determine whether continuous intravenous ketorolac infusion reduces pain in patients who are having percutaneous nephrolithotomy for kidney stone disease.
Eligibility Criteria
Inclusion Criteria
- Patients undergoing percutaneous nephrolithotomy for kidney stone disease
Exclusion Criteria
- History of nonsteroidal antiinflammatory drug allergy
- Asthma
- History of long-term opioid use
- Intraoperative blood loss greater than 300 mL
- Postoperative hemodynamic instability
- Active peptic ulcer disease
- Advanced renal impairment (Creatinine > 2.0 mg/dL)
- Bleeding diathesis
- Current use of probenecid
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT00765128). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.